Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Liabilities and Shareholders Equity (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $379.3 million as the latest value for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 251.26% to $379.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Jan 2026, up 671.76% year-over-year, with the annual reading at $295.7 million for FY2025, 543.64% up from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 was $379.3 million at Kestra Medical Technologies, up from $246.7 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $379.3 million in Q1 2026, with the low at $45.9 million in Q2 2024.
  • Average Liabilities and Shareholders Equity over 3 years is $223.7 million, with a median of $256.5 million recorded in 2025.
  • The sharpest move saw Liabilities and Shareholders Equity soared 543.64% in 2025, then surged 251.26% in 2026.
  • Over 3 years, Liabilities and Shareholders Equity stood at $45.9 million in 2024, then soared by 436.9% to $246.7 million in 2025, then soared by 53.77% to $379.3 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $379.3 million, $246.7 million, and $266.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.